BMS Bets On Growth In A Key Emerging Market – Japan
This article was originally published in PharmAsia News
Executive Summary
In 2011, Bristol-Myers Squibb stopped a five-year slide in Japan, turning sales into the black for the first time since 2005.
You may also be interested in...
Eliquis Delay Fuels Speculation About Advisory Committee Meeting
Three-month user fee extension for Bristol-Myers Squibb and Pfizer’s novel oral anticoagulant apixaban raises questions about whether an advisory committee panel will be convened after all, though the companies say none has been scheduled at this time.
BMS Looks To Utilize Cash Reserves To Break Into Japan's Top Tier
TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?